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Mycosis fungoides and Se´zary syndrome represent the
most frequent forms of cutaneous T cell lymphoma.
Both are characterized by skin infiltrating and/or
circulating malignant cells displaying a CD4FCD7–
phenotype in the majority of cases. Because an expan-
sion of CD4FCD7– cells may also be found in inflam-
matory dermatoses or in the aging process, we
evaluated, by flow cytometry, the relationship between
CD7 expression and the distribution of differentiation/
activation or homing antigens on peripheral blood
lymphocytes from 36 cutaneous T cell lymphoma
patients and from healthy donors. CD4FCD7– cells
were increased in all patients with cutaneous T cell
lymphoma. As a consequence, the CD7F/– ratio was
reduced in stage I–II mycosis fungoides (3.96 vs 6.55
in healthy donors), and inverted in stage III–IV MF
and Se´zary syndrome (0.28 and 0.12 respectively). In
Cutaneous T cell lymphomas (CTCL) comprise aheterogeneous group of lymphoproliferative dis-orders primarily affecting the skin. Mycosis fungoides(MF) and its leukemic variant, Se´zary syndrome(SzS) are the most frequent manifestations. MF is an
indolent cutaneous lymphoma characterized by slow progression
and a long survival, usually manifesting with flat patches or infiltrated
plaques. After a variable period of time, an evolution to skin
nodules and the spread to lymph nodes or other visceral sites may
occur. SzS is a more aggressive form, associated with extracutaneous
involvement and characterized by erythroderma, lymphadenopathy,
and circulating T helper malignant cells with cerebriform nuclei
(Diamandiou et al, 1996; Willemze et al, 1997).
Two main features characterize these cells. First, there is a CD7
negative phenotype in approximately 75% of patients (Haynes et al,
Manuscript received December 18, 1998; revised April 26, 1999;
accepted for publication June 9, 1999.
Reprint requests to: Enrico Scala, Istituto Dermopatico dell’Immacolata,
I.R.C.C.S. Via dei Monti di Creta, 104–00167 Rome, Italy.
Email: Escala@idi.it
Abbreviations: CLA, cutaneous lymphocyte antigen; CTCL, cutaneous
T cell lymphoma; MF, mycosis fungoides; SzS, Se´zary syndrome.
0022-202X/99/$14.00 · Copyright © 1999 by The Society for Investigative Dermatology, Inc.
622
the late stage of disease, the CD7F/– inverted ratio
was strictly related to the expression of CD15s, CD60,
and CD45R0, and the lack of expression of CD26
and CD49d. Interestingly, in leukemic patients, this
phenotype was also associated with peculiar morphol-
ogic (large size) or phenotypical (CD3dim expression)
characteristics. Furthermore, a progressive reduction
of circulating CD8F cells was also seen throughout all
stages of disease. The presence of these populations in
cutaneous T cell lymphoma at late phases of disease
and Se´zary syndrome suggests that all of these molec-
ules may play an important part in the activation
pathway and skin homing of circulating T cells in
lymphoproliferative disorders. Therefore, this may
constitute a distinctive feature in cutaneous T cell
lymphoma patients with more aggressive character-
istics. Key words: CD15s/CD26/CD45R0/CD60, VLA4.
J Invest Dermatol 113:622–627, 1999.
1981; Berger et al, 1982; Wood et al, 1986; Ladastide et al, 1990;
Harmon et al, 1996; Bogen et al, 1996). Second, there is a clear
predilection for skin homing (Picker et al, 1990). Thymocytes early
during ontogeny and normal circulating T cells express CD7, a
40 kDa glycoprotein member of the immunoglobulin gene super-
family (Lobach et al, 1985). CD7 negative T cells are normally
found in the peripheral blood at a low percentage (Reinhold et al,
1993), but an increase can be seen in the aging (Kukel et al, 1994)
and in a number of pathologic conditions, such as severe combined
immunodeficiency or inflammatory skin disease (Jung et al, 1986;
Moll et al, 1994). Recent studies suggest the involvement of this
antigen both in signal transduction and modulation of T lymphocyte
adhesive interactions (Shimizu et al, 1992). It is also known that
repeated mitogenic stimulation of naive CD41 cells from normal
individuals leads to the development of two memory subsets,
defined by the presence/absence of the CD7 antigen (Reinhold
et al, 1996). CD7 negative cells preferentially express CD60, a 9-
O-acetylated form of GD3 ganglioside found on 30–60% of
peripheral memory T lymphocytes, malignant T cells, some cell
lines and IL-4 producing cells (Kniep et al, 1993), and the cutaneous
lymphocyte-associated antigen (CLA). On the other hand, the
CD71 T cell subset shows an enhanced percentage of the CD27
antigen, a 100 kDa transmembrane glycoprotein belonging to the
tumor necrosis factor receptor (TNF-R) family, which provides
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costimulatory signals for T cell activation (Hintzen et al, 1993).
Both CD71 and CD7– T cells express similar levels of several
activation/differentiation antigens such as CD26, CD28, and
CD45R0 (Reinhold et al, 1996). CD26, the T cell’s activation
antigen dipeptidyl peptidase IV, is a 100 kDa glycoprotein that may
also interact with the extracellular matrix proteins fibronectin or
collagen (Kameoka et al, 1993). CD28 and CD7, which belong to
the immunoglobulin gene superfamily, are critically involved in T
cell co-stimulation, and provide comitogenic activation signals for
T cells (Koulova et al, 1991). Furthermore, cross-linking of CD7
and CD28 surface antigens modulates T cell adhesion (Shimizu
et al, 1992). CD45, a transmembrane glycoprotein with phosphatase
activity, has been proposed as a marker to discriminate memory
(expressing CD45R0 isoform) from unprimed (CD45RA) T cells
(Streuli et al, 1987; Akbar et al, 1988). Taken together, these
data indicate an important relationship between CD7 and these
activation/differentiation markers. Their combined study might
help with the identification of important cell subpopulations for
several disease statuses.
Another characteristic of leukemic cells in CTCL is their
commitment to skin homing (Heald et al, 1993). Trafficking of
T lymphocytes to the skin is mediated by the interaction of
carbohydrate ligands such as CLA and CD15s on the T cell surface
with E- or P-selectin expressed by dermal vascular endothelium
(Fuhlbrigge et al, 1997; Tietz et al, 1998). CLA is a fucosyltransferase
VII-mediated modification of P-selectin glycoprotein ligand-1
which allows binding to E-selectin (Picker et al, 1990; Fuhlbrigge
et al, 1997). Also, T cells expressing the variant type of sialyl Lex
(CD15s) defined by 2F3 monoclonal antibody (MoAb), show a
clear E-selectin-dependent adhesion to activated endothelial cells
and are usually committed to the skin (Ohmori et al, 1993;
Furukawa et al, 1994). The integrin VLA4 (CD49d) modulates the
migration of the lymphocyte through the vessel wall after binding
to VCAM-1 (cell adhesion molecule expressed on activated endo-
thelium). VLA4 also mediates the firm adhesion to the subendothel-
ial extracellular matrix and therefore is directly involved in the skin
homing of T lymphocytes (Savoia et al, 1992; Springer, 1994).
Based on these considerations, we investigated the correlation
between the expression of CD7 and the distribution of differenti-
ation/activation antigens or homing-related molecules in peripheral
blood lymphocytes (PBL) from CTCL patients at various disease
stages and in SzS cases.
MATERIALS AND METHODS
Patients Thirty-six patients (25 males, 11 females, mean age 64.9618.8 y)
with CTCL were included in the study. Table I summarizes the sex, age,
clinical stage, lymphomonocyte, and Se´zary cell count in each patient.
Eighteen healthy individuals (12 men, six women, mean age 50.668.4 y)
acted as normal controls. The diagnosis was based on physical examination,
histology, and immunohistology. Quantitation of Se´zary cells from each
patient was performed on blood film using Wright’s stain. Staging was
based on TNM criteria (Bunn et al, 1979). Five adult patients (four males
and one female) with severe atopic dermatitis and seven patients (five males
and two females) suffering from moderate to severe plaque-type psoriasis
(affected body surface areas ranging from 30 to 60%) were included as
inflammatory dermatoses controls. Systemic treatments were discontinued
in all patients studied at least 15 d before blood specimens were collected.
Three-color flow cytometry analysis In this study the following
MoAb were used: unconjugated rat anti-human CLA (PharMingen,
San Diego, CA); fluorescein isothiocyanate (FITC)-conjugated anti-CD7,
CD11a, CD15s, CD27, CD30, CD45R0, CD54, CD60, and CD95;
R-Phycoerythrin (PE) conjugated anti-CD26, CD28, CD45RA, CD49d
(VLA4), and CD69; FITC, PE, or peridin chlorophyll protein (PCP)
conjugated anti-CD3, CD4, or CD8 (Becton Dickinson Immunocytometry
System, Mountain View, CA). Three-color flow cytometry analysis was
performed as previously described (Scala et al, 1988). Briefly, fresh peripheral
venous blood samples from patients with CTCL and controls were collected
in tubes containing 1.5 mg of ethylenediamine tetraacetic acid-κ2 per ml
of blood. One hundred microliters of well-mixed whole blood was
delivered into the test-tube and placed in an ice-water bath. Erythrocytes
were lysed according to the manufacturer’s instructions using ammonium
Table I
Age/sex Clinical Lymphomonocyte Se´zary cell
stage cell count per µl count per µl
1 65/F IA 1020 ,10
2 65/M IA 1500 ,10
3 67/M IA 1500 ,10
4 75/F IA 1270 ,10
5 75/M IB 1300 ,10
6 52/M IB 1470 ,10
7 59/M IB 2109 ,10
8 70/M IB 1050 ,10
9 60/F IB 746 ,10
10 68/M IB 2540 ,10
11 87/M IIA 745 ,10
12 72/M IIA 489 ,10
13 62/M IIA 1840 ,10
14 63/F IIA 2269 ,10
15 65/M IIA 1952 ,10
16 64/M IIA 1155 ,10
17 78/F IIB 1927 ,10
18 61/M IIB 1630 ,10
19 75/M IIB 1013 ,10
20 48/M IIB 267 ,10
21 66/M IIB 1224 ,10
22 65/M IIB 493 ,10
23 40/M IIIA 1350 12
24 65/F IIIA 880 17
25 58/F IIIA 6129 367
26 38/F IIIB 1667 33
27 68/M IVA 1500 77
28 69/F IVA 2845 113
29 66/M IVB 12 620 378
30 87/F IVB 1200 12
31 78/M SzS 8800 5984
32 68/M SzS 4935 2072
33 59/M SzS 3640 3094
34 54/M SzS 4646 2462
35 69/M SzS 3321 2285
36 61/F SzS 9780 7628
chloride lysing solution (Ortho-mune lysing solution; Ortho Diagnostic
System, Raritan, NJ) for 10 min at room temperature. PBL were washed
and resuspended in cold phosphate-buffered saline (PBS) containing 2%
fetal bovine serum (FBS; GIBCO, Paisley, Scotland, U.K.) and 0.02%
natrium azide (NaN3) at 2 3 10
6 per ml. All the subsequent steps were
completed while keeping the cells in an ice bath. A total of 100 µl of cell
suspension was mixed with 10 µl of each MoAb and incubated in the dark
for 30 min at 4°C. After 30 min, cells were washed twice in cold PBS
and then resuspended in 300 µl of PBS containing FBS and NaN3 for
immediate flow cytometry analysis. An irrelevant mouse IgG1 MoAb
(Becton Dickinson) was used as a negative control.
For the determination of CLA positive cells, 100 µl of cell suspension
was mixed with 4 µl of HECA-452 (rat IgM MoAb to CLA, PharMingen)
and incubated at 4°C for 30 min. After two washes, 4 µl of PE-rabbit
anti-rat IgG was added and incubated in the dark at 4°C for 30 min. After
two additional washes, 4 µl of normal mouse serum was added to each
sample and after 10 min the other two MoAbs (PcP-CD3 and FITC-
CD4) were added. After 30 min of incubation in the dark at 4°C, cells
were washed twice and resuspended in 300 ml of PBS containing FBS
and NaN3 for immediate flow cytometry analysis. Staining with an
irrelevant rat IgM MoAb (Pharmingen) was used as a control.
Quantitative analysis for three-color flow cytometry was carried out
using an FAC-Scan instrument (Becton Dickinson). At least 10,000 events
were acquired in list mode, and all the data were analyzed by the CellQuest
software (Becton Dickinson). Live lymphomonocytes were electronically
gated by forward and right angle scatters.
Statistical analysis Statistical analysis was performed using SigmaStat
version 1.0 software (Jandel Corporation, San Rafael, CA). Differences
between percentages and absolute numbers were completed using the
Mann–Whitney U test and the Spearman rank correlation coefficient. The
tied p-values are provided.
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Table II
CD31 CD31 CD31CD41
% Absolute no. CD41 CD81 CD71 CD7–
% Absolute no. Absolute no. % Absolute no. % Absolute no.%
Healthy donors (18)
Mean6SD 72.568.2 12126169 59.668.8 7256142 32.868 4016116 86.767.2 6556106 13.267.3 97649
MF [I–II] (22)
Mean6SD 77.568.5 10486526 67.1614.3 7306464 25.6610.8 2456149 80.06611.5 5896404 20.2611.1 143677
Mann–Whitney U test — — — — p,0.03 p,0.002 — — — —
MF [III–IV] (8)
Mean6SD 88.865.3 257761616 88614.6 238861627 9.1169.4 1566114 21.9617.8 5226612 77.3617.9 215061438
Mann–Whitney U test p,0.0001 p,0.03 p,0.0001 p,0.05 p,0.0001 p,0.0001 p,0.0001 — p,0.0001 p,0.0001
SzS (6)
Mean6SD 85.5614.4 596664053 89.6610.2 541263976 8.369.6 4276540 11.265.2 4336244 88.7623.6 369162589
Mann–Whitney U test p,0.02 p,0.002 p,0.0001 p,0.0001 p,0.0001 — p,0.0001 — p,0.0001 p,0.005
RESULTS
Differentiation/activation markers We evaluated the expres-
sion of several differentiation/activation markers on circulating
CD41 T cells from 36 patients with CTCL (Table I) and 18
healthy individuals and compared the results.
The CD31CD41 lymphocyte percentage was slightly increased
in 22 patients with the early stages of disease but markedly increased
in the advanced stages of MF (eight cases, four patients having
diffuse erythroderma and four at the tumor stage) and SzS (six
cases). In addition, the absolute CD31CD41 lymphocyte count in
the later stages of MF and in SzS was increased compared with
controls (Table II). Also, the percentage and absolute number of
CD31CD81 lymphocytes was lower in stage I and II patients with
MF, and even more decreased in the late stage of MF when
compared with healthy donors. Therefore, a significant inverse
relationship between CD31CD41 cells and CD31CD81 cells was
observed (rs –0.83, p,0.001). Surprisingly, the absolute number of
CD81 cells was not different between patients with SzS and
controls (Table II).
In normal donors, CD71 lymphocytes were about 80% of total
T helper cells (CD71/– ratio: 6.55). Also, in MF cases in the
plaque–patch stage, CD71 lymphocytes outnumbered CD7–
lymphocytes, but a decrease of the CD71/– ratio (3.96) was noted.
On the contrary, in the late stages of MF and in SzS patients, an
inversion of the CD71/– ratio occurred (0.28 and 0.12, respectively).
The inversion of the CD71/– ratio in these patients was mainly
due to a significant expansion of both the percentages and the
absolute number of CD7 negative cells (p50.0001 by Mann–
Whitney U test). This increase was also observed, but at a much
lower level, in the earliest phase of disease (Table II). No age
differences were present between MF patients at late stage and
controls, whereas both MF patients at early phases of disease and
SzS cases were slightly older than healthy donors (Table I). We
observed only a slight, but not significant, increment of circulating
CD7 negative cells in psoriasis patients and no difference was
observed in atopic dermatitis patients (data not shown).
We then studied the expression of several other molecules such
as CD26, CD27, CD28, CD30, CD45R, CD60, CD69, and CD95
on CD41 T cells. As shown in Table III, no significant differences
in expression were noted comparing patients with MF at the
plaque–patch stage and healthy individuals. On the other hand, we
could detect a significant increase both in the percentage and the
absolute number of CD41 cells expressing CD60 and CD45R0
but lacking CD26 and CD45RA surface antigens in patients in the
late stages of MF and SzS patients (Table III). No significant
differences in expression of any of these markers between SzS cases
and MF patients with stage III or IV disease were ever seen.
Notably, the direct correlation between the percentage of CD7
negative cells and all of the antigens mentioned was observed
(Table IV). These data suggest that the coexpression of CD60 and
CD45R0 antigens in CD7/CD26 double negative cells might be
a distinctive feature of patients with CTCL in late stages of disease.
Among the other differentiation/activation markers studied, only
a small percentage increase (p,0.05) of CD271 T helper cells in
patients compared with controls was observed (64.1619.2 in
healthy donors vs. 74.7619.7 in the early stages of MF, 80.8613.9
in the late stages of MF and 81.9611.6 in SzS cases). No significant
difference in expression of CD30, CD69, and CD95 between
healthy donors and patients with CTCL was observed; however,
an abnormal expansion of CD28 negative cells in two patients with
SzS (50% and 39% of total CD41 cells respectively) and one patient
with stage IV MF (61% of total CD41 cells) was found. All
mentioned markers were not statistically different comparing
patients with psoriasis and atopic dermatitis to healthy individuals
(data not shown).
Homing-related molecules When we looked at the expression
of homing-related antigens, such as CD11a, CD15s, CD54, and
VLA4 within CD41 T cells, no difference between normal donors
and patients with stage I or II MF was observed (Table III).
Interestingly, patients with late stages of MF and patients with SzS
showed a significant increase in the number of CD41 T lymphocytes
expressing CD15s but lacking VLA4 (CD49d) (Table III). A direct
relationship between the percentage of CD7 negative cells and the
percentage of VLA4– and CD15s1 lymphocytes was also found
(Table IV). No significant differences in the expression of CD11a
and CD54 were found between our study groups (data not shown).
As previously suggested for differentiation/activation molecules,
these data led us to hypothesize that an atypical population of
CD7/VLA4 double negative but CD15s expressing T lymphocytes
might be present in the late stages of CTCL.
As it has been reported that CLA is increased in lymphoprolifer-
ative skin disorders (Picker et al, 1990), we also evaluated the
expression of this antigen. 68.2 6 18.1% of CD41 T lymphocytes
from patients with late stages of MF express CLA. In addition, a
coexpression of CLA and CD15s was also found (Fig 1).
T cell subset distribution in patients with SzS We then
wondered if further differences in T cell antigen expression could
be detected between patients with late stages of MF and SzS.
Surprisingly, no significant differences were noted in the expression
of the molecules we studied, with the exception of CD49d
expression on CD41 T cells (18.766.3% in SzS vs. 38.6618.1%
in the late stages of MF, p,0.03 by Mann–Whitney U test).
When we looked at the intensity of CD3 expression, three
patients with SzS showed a bimodal distribution of this antigen,
allowing for a discrimination between bright (normal) or dim
(atypical) intensity (Fig 2) as previously described (Bogen et al,
1996). We found that the percentage of CD3dim cells constantly
outnumbered the ‘‘bright’’ cell population. Interestingly, CD3dim
cells expressed CD60 but not VLA4 or CD7. On the other hand,
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Table III. Differentiation/activation and homing-related molecules within peripheral blood CD41 T cells
CD601 CD26– CD45R01 CD15s1 CD49d–
% Absolute no. % Absolute no. % Absolute no. % Absolute no. % Absolute no.
Healthy donors (18)
Mean6SD 23.6611.3 3016144 32.13613.4 3816175 52.4613.4 408691 23.4468.7 176657 25.3617.01 3716167
MF [I–II] (22)
Mean6SD 20.569.9 2046189 42.4621.06 4736460 55.1619.03 3856341 25.9610.06 1686108 23.6619.1 2916442
Mann–Whitney U test — — — — — — — — — —
MF [III–IV] (8)
Mean6SD 54.8615.1 156161181 92.163.7 267161467 78.8625 228562142 65.5622.6 172361354 63.1619.03 182661347
Mann–Whitney U test p,0.0001 p,0.006 p,0.0001 p,0.0001 p,0.01 p,0.0001 p,0.003 p,0.003 p,0.0002 p,0.02
SzS (6)
Mean6SD 67.6621.2 458564283 93.765.1 530562715 87.6612.01 369562325 79.9623.6 388962414 81.2617.25 486863838
Mann–Whitney U test p,0.0001 p,0.0001 p,0.0001 p,0.0001 p,0.0001 p,0.0001 p,0.0001 p,0.006 p,0.0001 p,0.0001
Table IV. Spearman rank order correlation between CD7
negative cell and activation, differentiation, or homing-
related antigens percentages
Correlation
coefficient (rs) p-value
CD601 0.75 ,0.001
CD45R01 0.42 ,0.03
CD15s1 0.67 0.003
CD26– 0.74 ,0.001
CD45RA1 20.45 ,0.01
CD49d– 20.49 0.02
Figure 1. Electronically gated CD4F cells coexpress CD15s and
CLA antigens.
all CD3bright cells were mostly VLA41 and CD71 but not CD60–
(Fig 2). In the remaining three patients with SzS, two lymphoid
populations were detected on the basis of cell size. In these cases
the larger sized (lymphoblastic) population was almost exclusively
CD31CD41CD601CD7– and VLA4–, resembling the phenotype
of the CD3dim T cells previously described. The smaller sized
subset of lymphocytes were mostly CD71, CD60– and VLA41.
None of these populations (CD3dim or lymphoblastic T cells) were
ever observed in other patients with MF or in healthy controls.
DISCUSSION
In this study we investigated the expression of several activation
and homing surface antigens on PBL in a cohort of 36 patients
with CTCL. Within the CD41 population of T cells, the number
of circulating lymphocytes expressing CD7 from patients with the
Figure 2. Three-color flow cytometric analysis of, respectively,
CD3/CD60/VLA4 and CD3/CD4/CD7 combination in a
representative SzS patient. Live lymphocytes were gated on forward
and side light scatter. A bimodal expression of CD3 was observed. CD3bright
and CD3dim T cells were gated in order to define their respective
phenotypic characteristics. CD3bright cells were mostly CD60– VLA41.
CD3dim lymphocytes express CD60 but not VLA4 antigen. Within
CD3bright cells, CD41 (and CD4–) cells were mostly CD71, whereas
CD3dim were all CD41 lymphocytes that had lost CD7 surface antigen.
In all cytograms, the lower left quadrants delimit the fluorescence intensities
obtained with appropriate isotype and fluorochrome-matched negative
control MoAb.
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patch/plaque stage of MF constantly outnumbered CD7 negative
lymphocytes. By contrast, an expansion of CD7– T helper lympho-
cytes occurred both in MF patients in stage III–IV and in SzS cases
with an inversion of the CD71/– ratio of 0.28 and 0.12, respectively.
These findings are in agreement with data from the literature
which describe a CD7– expansion in the majority of patients with
CTCL (Haynes et al, 1981; Berger et al, 1982; Wood et al, 1986;
Ladastide et al, 1990; Harmon et al, 1996; Bogen et al, 1996). It
must be noted, however, that such an increase in these cells may
also be found in inflammatory dermatoses (Moll et al, 1994) or in
the aging process (Kukel et al, 1994). For these reasons, we studied
the expression of many other surface antigens. We demonstrated
that the presence of cells lacking CD7 was directly linked both to
an increased percentage and absolute number of several activation/
differentiation antigens such as CD60 and CD45R0 and to a
decreased expression of other molecules such as CD26 and
CD45RA (Tables III and IV, Fig 2). Increased expression of the
CD60 antigen in patients with CTCL was already described by
Hansen et al (1993) but no correlation had been made with CD7–
cells. As it is known that CD7– cells respond preferentially to
several stimuli such as CD2, CD28, or CD60 MoAb, but not to
anti-CD3 (Carrera et al, 1988; Hansen et al, 1993), then the
increased number of CD7– CD601 cells we observed might have
a functional significance in these patients. In fact, in vitro challenge
of T cells from patients with CTCL with CD60, an antigen
independent activating molecule, results in frank activation of these
cells suggesting that this activation pathway may also be important
in vivo (Hansen et al, 1993). Furthermore, the increased expression
of CD45R0 surface antigen in these cells suggests that an expansion
of memory cells occurs in the late phases of MF and SzS, as both
CD45R0 and CD60 are coexpressed in those cells which switch
from a naive to a memory phenotype (Akbar et al, 1988; Kniep
et al, 1996).
Surprisingly, we found decreased expression of CD26 in circulat-
ing memory CD41 lymphocytes in the late phase of CTCL and
in SzS cases (Table III). CD41CD7– lymphocytes normally express
CD26, an important accessory molecule for T cell activation
(Reinhold et al, 1996). We do not currently know what the
significance of this downregulation is, but it is known that there is
decreased responsiveness to mitogenic stimuli seen in PBL from
patients with SzS (McCusker et al, 1997). As CD26 expression is
strictly related to protein kinase C activity (Hollsberg et al, 1993),
the absence of CD26 found in our series might be related to
downregulation of protein kinase C activity and, therefore, may
explain the above-mentioned abnormal mitogen responsiveness in
patients with SzS. It would be of interest to assess the protein
kinase C activity in cell lines from patients with SzS in order to
validate this supposition.
Another important characteristic of CTCL leukemic cells is their
epidermotropism. Several authors have reported that epidermo-
tropic lymphocytes are primarily CLA1 T cells expressing CD45R0
(Picker et al, 1990; Heald et al, 1993) and that the expression of
CLA antigen is strictly related to the extent of CTCL disease
(Borowitz et al, 1993). In this study we also show that cells
expressing CLA complex and CD15s are expanded in the late
phase of disease and that these antigens are coexpressed (Fig 1).
This indicates that in PBL of patients with CTCL, an increase of
skin committed memory T lymphocytes takes place. An interesting
finding was the lack of VLA4 (CD49d) expression in PBL of
patients with stage III–IV MF and patients with SzS (Table III) in
the presence of an unmodified absolute number of VLA41 cells.
On the contrary, VLA4 is highly expressed on T lymphocytes that
infiltrate the skin (Savoia et al, 1992). This difference might reflect
the fact that our study was performed on circulating T cells, and
did not address the phenotype of the same cells in lymph nodes or
skin, where lymphocytes may display different markers. Another
explanation of this phenomenon, however, could be that CD7–
circulating T cells, which lack the VLA4 antigen, might represent
the counterpart of skin infiltrating lymphocytes that have lost their
epidermotropic properties. In fact, VLA4 is thought to exist in
multiple activation states (Woldemar Carr et al, 1996; Newhan
et al, 1998): inactive, partially active, and fully active. In the inactive
state, this integrin is unable to interact with VCAM-1 or fibronectin.
In the partially active state, it binds VCAM-1 but not fibronectin.
In the fully activated state, VLA4 is able to bind both ligands.
Consequently, the absence of VLA4 on cells expressing CD15s
may lead us to hypothesize that CD7 negative T cells in peripheral
blood of patients with late-stage disease, although committed to
the skin, are unable to migrate through the vessel wall and firmly
adhere to the extracellular matrix spaces because of the defective
expression of VLA4. The above-mentioned downregulation of
CD26, a molecule which may also interact with extracellular matrix
proteins (Kameoka et al, 1993), adds more efforts to this scenario.
Nevertheless, further functional experimental studies are required
in order to confirm this hypothesis.
Findings observed in patients with SzS deserve a separate debate.
In those patients who are characterized by a large amount of
circulating malignant cells, the aberrant distribution of all described
antigens may be strictly related to a direct measurement of neoplastic
cells. All patients studied with SzS showed two circulating T cell
subsets distinguished by phenotype (bright and dim bimodal CD3
expression) as previously described (Bogen et al, 1996) or physical
(cell size) parameters. Whereas no difference in antigen expression
was observed in CD3bright or smaller-sized cells from normal
donors, CD3dim or the large-sized lymphoblast subset showed a
CD601CD45R01 phenotype associated with the lack of expression
of CD7 and CD49d surface antigens (Fig 2). Interestingly, patients
with MF in late phases of the disease showed similar phenotypical
features suggesting these populations might constitute a typical
expansion in patients with CTCL with a more aggressive character-
istic. Of course, it would be of interest to evaluate whether these
cells represent a malignant or reactive population. The correlation
of serial determinations of these markers and tumor burden would
also be of interest.
As widely reported, an increment of CD31CD41 cells could be
observed especially in patients with MF stage III–IV and SzS.
CD31CD81 cells, however, tended to diminish from MF stage I–
II through MF stage III–IV. These data support the evidence that
a reduced tumor-specific cytotoxic activity might occur in CTCL
disease (Seo et al, 1998) and therefore might be responsible for
tumor progression from the earliest phases of disease. Whereas this
percentage decrement is also observed in patients with SzS, no
difference was noted in the absolute number. This might suggest
the decrement of the CD8 compartment is a paraneoplastic phe-
nomenon. Alternatively, the preserved absolute number of CD8
cells may represent a reactive phenomenon vs. leukemic cells.
In conclusion, the flow cytometry panel used in this study
allowed us to define a cell population of PBL in patients with
CTCL with interesting hallmarks of activation and skin homing
(CD31CD41CD7–CD15s1CD26–CD45RO1CD49d–CD601).
This cell population was clearly seen in patients with stage III–IV
MF as well as in individuals with SzS where it was also associated
with peculiar morphologic and phenotypical parameters (large size,
CD3dim). The further characterization of this cell population
through clonality assessment and the correlation to disease progres-
sion through serial analysis, comparing these tests with a more
sensitive severity score, will give clues on the functional and
pathologic implications of these cells.
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